CINECA IRIS Institutional Research Information System

ROSSINI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.932
AS - Asia 1.785
EU - Europa 1.198
SA - Sud America 328
AF - Africa 97
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.344
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.867
SG - Singapore 627
CN - Cina 413
IT - Italia 395
HK - Hong Kong 315
BR - Brasile 268
VN - Vietnam 186
DE - Germania 185
SE - Svezia 115
GB - Regno Unito 111
FR - Francia 109
BG - Bulgaria 81
FI - Finlandia 50
IN - India 46
RU - Federazione Russa 42
CA - Canada 39
CI - Costa d'Avorio 38
JP - Giappone 36
BD - Bangladesh 28
TR - Turchia 27
AR - Argentina 25
PL - Polonia 23
MX - Messico 18
NL - Olanda 18
ID - Indonesia 15
IQ - Iraq 14
NG - Nigeria 13
ES - Italia 12
UA - Ucraina 11
KR - Corea 9
PH - Filippine 9
CO - Colombia 8
UZ - Uzbekistan 8
ZA - Sudafrica 8
CZ - Repubblica Ceca 7
EC - Ecuador 7
SN - Senegal 7
AT - Austria 6
IE - Irlanda 6
LT - Lituania 6
SA - Arabia Saudita 6
CL - Cile 5
EG - Egitto 5
KG - Kirghizistan 5
MA - Marocco 5
MY - Malesia 5
PK - Pakistan 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
DZ - Algeria 4
VE - Venezuela 4
AZ - Azerbaigian 3
BY - Bielorussia 3
ET - Etiopia 3
KE - Kenya 3
KH - Cambogia 3
LV - Lettonia 3
NP - Nepal 3
PE - Perù 3
PT - Portogallo 3
PY - Paraguay 3
SY - Repubblica araba siriana 3
TN - Tunisia 3
AO - Angola 2
BB - Barbados 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
KW - Kuwait 2
NZ - Nuova Zelanda 2
OM - Oman 2
PS - Palestinian Territory 2
RO - Romania 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
CR - Costa Rica 1
DK - Danimarca 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
IM - Isola di Man 1
IR - Iran 1
JM - Giamaica 1
KZ - Kazakistan 1
LB - Libano 1
LY - Libia 1
MD - Moldavia 1
MT - Malta 1
NA - Namibia 1
PA - Panama 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
TG - Togo 1
Totale 6.343
Salva come PNG Salva come JPEG
Città #
Singapore 354
Ashburn 322
Hong Kong 307
Santa Clara 266
Fairfield 221
Dallas 208
Woodbridge 202
San Jose 168
Chandler 126
Houston 125
Shanghai 108
Seattle 104
Wilmington 95
Cambridge 85
New York 81
Sofia 81
Ann Arbor 72
Beijing 70
Boardman 64
Florence 60
Los Angeles 59
Ho Chi Minh City 58
Munich 54
London 47
Pisa 45
Abidjan 38
Princeton 37
Lawrence 36
Hanoi 33
Milan 31
Lauterbourg 30
Tokyo 30
Cascina 27
Frankfurt am Main 26
Medford 25
São Paulo 25
Ottawa 24
Serra 23
Redondo Beach 21
Rome 21
Turku 21
Dearborn 19
Helsinki 19
Warsaw 19
Bremen 18
Seacroft 18
Turin 18
Hefei 17
Ogden 17
Des Moines 16
Orem 16
Istanbul 15
Buffalo 13
Council Bluffs 13
Genoa 13
Lagos 13
Lancaster 13
Düsseldorf 12
Nanjing 12
Fuzhou 11
San Diego 11
Rio de Janeiro 10
Verona 10
Seoul 9
Da Nang 8
Denver 8
Dong Ket 8
Kent 8
Atlanta 7
Boulder 7
Chicago 7
Dakar 7
Fortaleza 7
Haiphong 7
Kunming 7
Montreal 7
Paris 7
Phoenix 7
Porto Alegre 7
Quanzhou 7
Redwood City 7
Tashkent 7
Baghdad 6
Chennai 6
Mumbai 6
Brooklyn 5
Dhaka 5
Dublin 5
Guarulhos 5
Montevideo 5
Positano 5
Amsterdam 4
Ankara 4
Avaré 4
Boston 4
Curitiba 4
Guangzhou 4
Hebei 4
Hyderabad 4
Hải Dương 4
Totale 4.376
Salva come PNG Salva come JPEG
Nome #
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 203
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 191
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 188
TAS-102 for the treatment of metastatic colorectal cancer 180
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 174
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 169
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 168
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 166
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 164
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 163
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients 161
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 157
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 156
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 156
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 151
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer 151
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 150
A still missing piece of the FIRE-3 puzzle 148
Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram 140
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 138
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 132
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 130
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 129
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 128
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 121
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 121
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 120
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 119
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study 116
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 112
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study 110
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 104
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 102
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 102
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 101
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 99
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 98
null 98
Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence 97
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 95
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy 95
Individual patient data meta-analysis of folfoxiri plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer 95
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib 90
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 87
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study 84
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer 70
null 69
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 68
TRIBE2 results and toxicity – Authors' reply 67
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 56
KDR genetic predictor of toxicities induced by sorafenib and regorafenib 54
TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply 51
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis 44
Merkel cell carcinoma of the retroperitoneum with no identifiable primary site 25
Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC 18
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study 4
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation 3
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO 3
Totale 6.491
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.416
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.416
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202182 0 0 0 0 0 0 0 0 0 0 24 58
2021/2022317 4 4 7 5 58 56 4 10 18 37 24 90
2022/2023528 51 75 38 36 46 51 28 30 92 2 70 9
2023/2024424 18 36 59 34 60 59 27 16 9 14 48 44
2024/20251.732 34 64 39 80 179 230 128 92 162 186 192 346
2025/20262.054 157 239 259 228 252 152 283 145 120 194 25 0
Totale 6.491